Several cancers are characterized by large-scale mtDNA deletions. We previously provided evidence that one of these deletions has potential utility in resolving false from true-negative prostate needle biopsies. This study was to assess the clinical value of this deletion in predicting re-biopsy outcomes. We used a quantitative polymerase chain reaction assay to measure the levels of the deletion in individual negative needle biopsies from 101 patients who had a repeat biopsy within a year with known outcomes. Using an empirically established cycle threshold (Ct) cutoff of 31, and the lowest Ct for each patient as diagnostic of prostate cancer, as well as the histopathologic diagnosis on second biopsy, we calculated the clinical performance of the deletion. The Ct cutoff at 31 gave a sensitivity and specificity of 84 and 54%, respectively, with the area under a receiver-operating characteristics curve of 0.749. The negative predictive value was 91%. The assay was able to predict the presence of a missed tumor in 17 out of 20 men a year before diagnosis. This ancillary test appears to identify men who do not require a repeat biopsy with a high degree of certainty. The results suggest that the majority of men with atypical small acinar proliferation have a concurrent missed tumor and therefore require close monitoring for early detection.
Introduction
In the developed world, prostate cancer (PCa) remains the most frequent noncutaneous malignancy diagnosed in men over the age of 50 years; however, the case fatality of PCa is lower than many cancers. The decreased mortality is attributable to early detection of curable tumors and the slow natural history of many PCas. Early detection is achieved by increased awareness coupled with diligent digital rectal examination and PSA screening regimes. Although the PSA assay continues to be important in PCa management, it is quite inaccurate as a screening test. Several nonmalignant conditions including BPH and prostate infections can cause elevated PSA. 1 The positive predictive value of an elevated PSA is 35%. Between 15 and 30% of men with negative biopsies harbor PCa. In these cases, the negative results are accounted for by sampling error. [2] [3] [4] [5] Men whose biopsies show high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) have a 24-41% risk of underlying PCa that is identified on repeat biopsy. 6 Cancer has been reported in up to 100% of ASAP cases. 7 These findings highlight the need to re-biopsy patients with ASAP/HGPIN within 6-12 months.
Men with an elevated PSA are at increased risk for PCa. A single negative biopsy is not sufficient to exclude the diagnosis with certainty. Progressive rise in the PSA after an initial negative biopsy causes further anxiety and is often considered an indication for requiring a second biopsy. 8 An ancillary diagnostic test to rule out cancer without a repeat biopsy would have many advantages.
We previously reported the potential clinical value of a 3.4 kb mitochondrial DNA deletion that shows the concept of field effect or cancerization. 9 This could resolve negative prostate biopsies into true-and falsenegative categories. However, of the 96 patients in the validation study that provided proximal biopsy samples, only 48 had accompanying malignant biopsy cores for comparative analysis of test performance. Though many of these patients (30) had only a single biopsy, the 3.4 kb deletion was accurate in predicting the presence of a malignant focus in 67% of the patients. However, the performance of the deletion improved to 78% when we examined 18 patients who had two or more previous samples. This suggests that the marker could predict the outcome for the patient with a rising PSA and negative initial biopsies with a high degree of accuracy. 9 This study was designed to establish the 3.4-kb deletion biomarker cutoff that had the highest predictive accuracy for the results of subsequent biopsies. The findings should form the basis for the subsequent evaluation of this marker on prostate re-biopsy outcomes.
Materials and methods

Patients and samples
All patients were consented and samples obtained in accordance with the ethical guidelines of the Trafalgar Ethics Board (Oakville, Canada) that operates in accordance with the Tri-Council Policy Statement on Ethical Conduct of Research Involving Humans.
A total of 101 patients who have had a follow-up biopsy within 1 year of an initial negative biopsy for suspected PCa were recruited for the study. Sections (20 mm) from the six representative anatomic regions of the prostate (right apex, right mid, right base, left apex, left mid, left base) of the initial negative biopsies were obtained. It should be noted that by conventional modern practice, each patient received between 10 and 12 core biopsies; however, for logistic reasons we tested only cores representing six anatomic areas of the prostate. In all, a total of 595 (instead of 606) biopsies were analyzed. Eleven patients provided 5 cores each (instead of the 6 requested cores). The biopsies span a period between 1997 and 2008. On second biopsy, 20 patients were found to have cancer, with the remaining found to be benign. Ten of the PCa patients subsequently had prostatectomies for treatment of PCa.
DNA extraction and target amplification
DNA was extracted from 20 mm prostate needle biopsy sections using a QIAamp DNA Mini Kit (Qiagen, Mississauga, Ontario, Canada). Negative extraction controls were included and were monitored for amplification. Samples were quantified, diluted to 2 ng ml À1 and distributed to master template 96-well plates. Polymerase chain reaction (PCR) amplification was performed with PerfeCta Sybr Green Supermix (Quanta Biosciences, Gaithersburg, MD, USA). The following reaction conditions were used: 1 Â PerfeCta Sybr Green Supermix, 0.25 mM forward primer, 0.25 mM reverse primer (primer sequences available upon request), 20 ng template DNA in a 25 ml reaction volume. PCR was performed using the following cycling parameters: 95 1C for 2 min to activate the polymerase, followed by 45 cycles of 95 1C for 30 s, 30 s annealing at optimized primer temperatures: 61.5 1C for total mtDNA and tumor necrosis factor, 64.4 1C for deletion-specific primer and extension at 72 1C for 30 s. Plate reads were performed after each extension cycle. A 10-min final extension at 72 1C was performed before the melting curve analysis (70-95 1C, reading every 1 1C and holding for 3 s). The Opticon 2 and Chromo4 Real-Time Detector Systems (Bio-Rad Laboratories, Mississauga, Ontario, Canada) were used for PCR. One negative PCR control was included on every amplification plate for each primer set as well as seven standards for normalization purposes. These standards were serial dilutions of the target amplicon generated with conventional PCR, purified, quantified and diluted such that the seven standards were at concentrations of 3.85 ng, 0.385 ng, 38.5pg, 3.85pg, 0.385pg, 38.5fg and 3.85fg. Analysis of any given plate required a minimum of four standards.
Statistical analysis
The cycle threshold (Ct) of the 3.4 kb deletion was compared to the Ct of total amount of mtDNA (12S rRNA gene) and the amount of nuclear DNA (tumor necrosis factor). A tumor necrosis factor Ct of 440 for a sample was considered a failed reaction because this reflected insufficient template input. This restriction resulted in seven failed patient samples, which were removed from further analysis. Template DNA (10 ng) was seeded into each well for the quantitative PCR assay. Because tumor necrosis factor measured template input, the Ct variance across all samples was within 1 cycle; hence further analysis relied solely on 3.4 kb deletion Ct.
The mean and standard errors were calculated for each tissue classification. Two-by-two tables were constructed from the Cts for cancer and benign outcomes, and used to compute assay performance. Similarly, with reference to second biopsy outcomes, receiver-operating characteristics (ROC) curves were constructed for deletion Cts and the area under the curves was computed. All the tests were two-sided and statistical significance was considered at a P-value o0.05. SPSS version 13 (SPSS, Chicago, IL, USA) was used for all statistical analyses.
Results
The clinical and demographic data for all 101 subjects are summarized in Table 1 , and the pathological characteristics of the malignant patients are found in Table 2 . The mean (±s.d.) age, PSA and duration between biopsies for the participants were 60.64 ( ± 7.99) years, 7.09 (±4.93) ng ml À1 and 7.72 (±5.27) months, respectively. The group with ASAP was significantly younger than other patients (P ¼ 0.05). On the initial biopsy (tested in this assay), 8 patients had no histopathologic findings in any of their biopsies, 15 had isolated ASAP, 28 had isolated PIN, 7 had both ASAP and PIN, and 43 had findings such as hyperplasia, atrophy and prostatic inflammation. The majority of patients with subsequent diagnosis of cancer appear to have limited cancer (o50% core involvement, Gleason score o7 and o3 cores involved, see Table 2 ). Seven patients were excluded from further analysis because their samples failed to meet assay quality standards. Hence, the final data output based on 94 patients is composed of 20 malignant and 74 benign biopsies.
Because the Cts of our previous assays were generally high, 9 we optimized the assay to improve efficiency and specificity. We redesigned the primers for the deletion and this dropped the annealing temperature from 66 to 64.4 1C. Importantly, in this study Sybr Green reagents were used that have been specifically optimized for efficiency and sensitivity. All of these changes culminated in efficient deletion target amplification. The efficiencies for all runs in this assay were tight and mtDNA assay for making prostate re-biopsy decision K Robinson et al 480% compared to the highly variable efficiencies (60-80%) from the previous study.
In our previous study benign, malignant and histologically normal-appearing biopsies adjacent to a malignant focus were tested. The greatest separation of assay scores was achieved between the malignant and benign biopsies. However, this study assayed only biopsies showing either benign histology, ASAP or HGPIN. Hence to establish a usable assay cutoff for accurate delineation of benign versus malignant prostates, we used only biopsies without suspicious histological findings and those with a subsequent diagnosis of cancer. We identified 8 patients (48 core samples) that met the criteria for benign disease and 14 malignant patients (84 samples) were selected. The mean Cts for benign and malignant cases were 32.3 and 29.4, respectively, indicating a 7.9-fold difference in the levels of the deletion between the two groups. By testing the sensitivity and specificity using an ROC curve, the optimal Ct for accurate prediction of a positive re-biopsy outcome was 31. Thus, the positive likelihood ratio of a missed concurrent tumor increases or decreases with decreasing or increasing Ct, respectively (Figure 1 ). At this Ct cutoff, there was a statistically significant mean Ct difference between the two groups (P ¼ 0.001). A sensitivity of 79% and a specificity of 88% were achieved. Assay performance by ROC showed an AUC of 0.893 (95% CI; 0.754-1.031) (Figure 2) .
The 31-Ct cutoff was used to test the outcomes of all samples in a blinded fashion. Our initial data analysis revealed that a disproportionately high number of prostates with initial or subsequent findings of ASAP were called malignant by the assay. These were removed and the remaining benign samples were tested separately. The difference between the mean Cts of the benign and malignant samples was significant at P ¼ 0.001. In reference to the histopathologic diagnosis on second biopsy, the assay had a sensitivity of 84% and a specificity of 54%. In men with initial negative biopsies, the false-negative rate was low and the negative predictive value was 91%. The AUC was 0.749 (95% CI; 0.625-0.873) (Figure 3) .
Of the 101 patients in this study, 22 had ASAP on initial biopsy of which 10 were diagnosed with cancer within a year. This rate (45.5%) of cancer on re-biopsy of patients with ASAP is consistent with other reports. 10 The assay also predicted the presence of concurrent cancer in 8 of the remaining 12 subjects who had no cancer on re-biopsy. Six patients with initial negative biopsies were found to have ASAP on re-biopsy, and the assay predicted the presence of tumor on the initial mtDNA assay for making prostate re-biopsy decision K Robinson et al biopsy in all six patients. Thus, 78% of the cases with ASAP on either the initial or subsequent biopsy were flagged as having cancer by the assay (Figure 4) . The extent of the field alterations in the prostate defined by the 3.4-kb mitochondrial genome deletion is unknown. However, given that the deletion was able to predict a positive biopsy in 17 out of 20 (85%) individuals with cancer a year prior, we envisioned this as an early event that might involve multiple or large areas of the prostate. To gain an insight into the possible extent of this field effect, we looked at the number of cores called positive by the assay in each malignant patient. Of the 17 positive cases, 11 had more than 3 positive biopsies, which is suggestive of an extensive field effect ( Table 2) .
The archived samples used for the study were collected between 1997 and 2008 (spanning 12 years). Because both the time of fixation before embedding and age of the block adversely affect nucleic acid quality, we mtDNA assay for making prostate re-biopsy decision K Robinson et al looked at how these affected assay performance. There was no significant correlation of Cts and PCR efficiencies with block ages, indicating the lack of PCR interference by block ages. This finding is likely due to the efficiency of the DNA extraction from formalin-fixed samples using QIAmp kits, as well as the small-sized amplicon (273 bp) targeted by the quantitative PCR assay.
Discussion
The reliance on PSA screening for making biopsy decisions suggests that many men (especially those with mildly elevated PSA results) who undergo transrectal biopsy for PCa diagnosis will appear to be negative for cancer on initial biopsy. A repeat biopsy of this population within 5 years will reveal the presence of cancer in up to 30% of the patients, indicating that the prostate biopsy procedure is associated with a high sampling error. These high-risk men whose initial biopsies appear negative would benefit from accurate ancillary tests that establish the risk of PCa in individual patients. This clinical study was conducted with two primary objectives: first, to establish a clinically usable cutoff Ct, and second, to assess the performance of the assay in accurately predicting re-biopsy outcomes using the established Ct cutoff. In the optimized assay, a Ct cutoff of 31 gave the best performance, with a sensitivity of 84%, an NPV of 91% and an area under the ROC curve of 0.749.
These results are due to the presence of a field effect. A number of investigators have confirmed the concept of precancerous molecular events in normal-appearing cells using different markers. [11] [12] [13] The obvious benefit of such field biomarkers is in the selection of men at high risk of cancer for close monitoring, while reassuring the low-risk population.
PCa is ultimately found in people diagnosed with ASAP at a rate of 42-100%. Indeed, several authors have emphasized that the diagnosis of ASAP may provide false reassurance, because it is in fact infiltrating carcinomas in many cases.
14 It is not surprising that a molecular test will be positive in most ASAP cases. These men are high risk for PCa. The few remaining are unlikely to have PCa, and the mandate to re-biopsy could be relaxed.
The field concept posits that tumors develop in molecularly preconditioned fields. Histologically normal-appearing cells adjacent to most cancers contain genetic imprints indicative of malignancy. These molecular alterations associated with cancer fields afford an enormous opportunity for cancer management. Several groups have confirmed field cancer effects in prostatic tissues. 12, 15, 16 Chemoprevention or early detection strategies would benefit from the profiling of cancer field biomarkers in high-risk populations. A histologically normal surgical margin may warrant molecular examination to preclude submicroscopic involvement. 17 An underutilized advantage of the field concept of carcinogenesis lies in improving needle biopsy sampling errors by profiling the apparently normal biopsies. Negative prostate biopsies in high-risk patients may benefit from field profiling. We show that a single mitochondrial deletion assay for field effects in prostatic tissue has significant potential as a biomarker for PCa.
